Current literature does not provide evidence for a preferred third-line treatment in nonsystemic JIA, and therefore, current treatment guidelines do not give preference on one specific biological therapy after failure on both MTX and TNF blockade. This evidence concerns the gene TNF and juvenile idiopathic arthritis.